10x Genomics (TXG) Current Deferred Revenue (2018 - 2026)

10x Genomics has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $34.5 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $34.5 million, up 2.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.5 million (up 2.93% YoY), and the FY2025 annual result was $34.4 million, up 3.71% from the prior year.
• Current Deferred Revenue came in at $34.5 million for Q1 2026 at 10x Genomics, roughly flat from $34.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $34.5 million in Q1 2026 to a low of $5.4 million in Q1 2022.
• The 5-year median for Current Deferred Revenue is $22.0 million (2023), against an average of $20.9 million.
• Across the five-year window, Current Deferred Revenue jumped 182.53% in 2024 and retreated 26.45% in 2025, its largest moves.
• 10x Genomics' Current Deferred Revenue stood at $11.0 million in 2022, then jumped by 99.09% to $22.0 million in 2023, then jumped by 51.02% to $33.2 million in 2024, then grew by 3.71% to $34.4 million in 2025, then rose by 0.29% to $34.5 million in 2026.
• The last three Current Deferred Revenue figures came in at $34.5 million (Q1 2026), $34.4 million (Q4 2025), and $22.1 million (Q3 2025), per Business Quant data.